RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing precision medicines to treat rare neuroendocrine diseases. The company concentrates on advancing melanocortin-4 receptor agonists designed to address hyperphagia and severe obesity resulting from impaired signaling pathways in the brain. Its primary marketed therapy is IMCIVREE, which is authorized to manage weight and control hunger in adult and pediatric patients with rare conditions such as Bardet-Biedl syndrome and specific genetic deficiencies involving pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor genes. Beyond its approved treatments, the company is evaluating earlier-stage investigational drug candidates, including bivamelagon and RM-718, for hypothalamic obesity and Prader-Willi syndrome.

The company has obtained regulatory approvals, market access, or named patient sales across more than twenty-five countries beyond the United States, including territories within the European Union, the United Kingdom, and Canada. As of February 1, 2026, the company employed 414 individuals, with 126 staff members situated across 11 countries outside North America. The text does not state the company's headquarters location.

Summary of the business section of Rhythm Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 1, 2026, we had 414 employees – including 126 employees in 11 countries outside of North America, and we believe our employees are committed to learning from and collaborating with each other, each contributing to our mission.”